Engaging Hearts and Minds with Compelling Marketing Communication
With a strong foundation in the advertising industry, I specialize in developing and executing strategic branding and omnichannel campaigns.
This expertise has paved my way to roles at leading Nordic and global pharmaceutical and MedTech organizations as responsible of global brand strategy, value communication, disease awareness, product launch campaigns, and omnichannel communication.
I am passionate about crafting compelling omnichannel communication that resonates with key audiences, driving meaningful changes in knowledge, attitudes, and behaviours, and ultimately boosting both disease and brand awareness.
It takes one to know 1, and to make a meaningful difference for others
For more than 50 years I've been living with type 1 diabetes. I've not always been vocal about it. However, one day I realised the meaningfulness of sharing what it's like to live with type 1 diabetes.
My background within the field of life science and communication encouraged and empowered me to be the voice of my peers.
Knowledge is empowerment
My engagement in the diabetes community ensured my enrolment in EUPATI; a pan-European education (supported by Efpia and IMI) on medicines development, clinical trials, medicines regulations, HTAs, and how to ensure the voices of patients throughout the R&D process.
Hence, I'm familiar with the pharmaceutical value chain, overall aspects of clinical drug development, and my global network consists of EUPATI Fellows, KOLs, and people living with diabetes.
Please see the next column for examples of diabetes advocacy, and don't hesitate to get in touch, if you're interested in hearing more e.g., 'From pork to pump - five decades of milestones within diabetes treatment'.
Bridging the gap between the diabetes community and industry
Advocacy work
As part of the CODIAC (Copenhagen Diabetes Consensus) project group, I've provided input to the consensus paper on ‘User-involvement in diabetes care, prevention and research’.
The findings were presented at a conference on October 26-27, 2021 where I attended as a panellist.
Furthermore, as a board member for type1, a Danish diabetes organisation, I was responsible of developing the strategic foundation, omnichannel communication, presenting the organisation for key stakeholders, facilitating network meetings, and speaking at multiple events.
Speaking at the following meetings and events
- 'From pork to pump - five decades of milestones within diabetes treatment', presentations to colleagues at Novo Nordisk HQ (2018-19)
- Patient 3.0, DLI Conference on Patient Empowerment (2015)
- The Patient Perspective to the Danish Sanofi organisation (2015)
- On WDD sharing perspectives on T1D to Novo Nordisk Scandinavia (2014)
- The user perspective of insulin pumping, Abbott Diabetes Forum, conference for 85 diabetes nurses (2005)